Damla Alkaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Damla Alkaya has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Açelya Yilmazer
Ankara University
3 shared publications - Sanjiv Dhingra
University of Manitoba
2 shared publications Ahmet Ceylan
Department of Histology Embryology Faculty of Veterinary Medicine Ankara University Ankara 06070 Turkey
1 shared publication- Anna-Maria Pappa
Khalifa University of Science and Technology
1 shared publication - Arzu Hazal Aydin
Aksaray Eğitim ve Araştırma Hastanesi
1 shared publication Açelya Yilmazer
1 shared publication
Latest Publications
- Open Access
- 24 August 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (35) , 24189-24232
MXene Chemistries for Biomedicine: On-Body, In-Body, and Beyond
MXenes, a rapidly expanding family of two-dimensional transition-metal carbides, nitrides, and carbonitrides, have gained considerable attention as highly versatile nanomaterials for biomedical applications owing to their high electrical conductivity, chemically tunable surfaces, mixed ionic–electronic transport, and controllable redox activity. This review provides a structured overview of MXene-based biomedical technologies, organized by their functional interaction with the human body. We first examine on-body applications, highlighting MXene-enabled wearable, epidermal, and implantable bioelectronics. We then discuss in-body applications, including regenerative medicine, advanced cancer therapies, and antimicrobial strategies, emphasizing how MXene chemistry regulates biological interactions and therapeutic performance. Finally, we address applications outside the body, such as biosensing and diagnostic platforms, where MXenes enhance sensitivity, signal transduction, and imaging capabilities. Beyond summarizing recent advances, this review critically analyzes current gaps in knowledge, including long-term biocompatibility, degradation pathways, immune interactions, and structure–activity relationships, which currently limit clinical translation. We conclude by outlining key future directions, including sustainable synthesis, oxidation-resistant and fluorine-free MXenes, and the integration of artificial intelligence to accelerate materials discovery and application-specific design. Together, these insights position MXenes as chemistry-programmable nanoplatforms with strong potential to bridge on-body, in-body, and outside-the-body biomedical technologies.
- 24 August 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (35) , 24189-24232
Open AccessMXene Chemistries for Biomedicine: On-Body, In-Body, and Beyond
MXenes, a rapidly expanding family of two-dimensional transition-metal carbides, nitrides, and carbonitrides, have gained considerable attention as highly versatile nanomaterials for biomedical applications owing to their high electrical conductivity, chemically tunable surfaces, mixed ionic–electronic transport, and controllable redox activity. This review provides a structured overview of MXene-based biomedical technologies, organized by their functional interaction with the human body. We first examine on-body applications, highlighting MXene-enabled wearable, epidermal, and implantable bioelectronics. We then discuss in-body applications, including regenerative medicine, advanced cancer therapies, and antimicrobial strategies, emphasizing how MXene chemistry regulates biological interactions and therapeutic performance. Finally, we address applications outside the body, such as biosensing and diagnostic platforms, where MXenes enhance sensitivity, signal transduction, and imaging capabilities. Beyond summarizing recent advances, this review critically analyzes current gaps in knowledge, including long-term biocompatibility, degradation pathways, immune interactions, and structure–activity relationships, which currently limit clinical translation. We conclude by outlining key future directions, including sustainable synthesis, oxidation-resistant and fluorine-free MXenes, and the integration of artificial intelligence to accelerate materials discovery and application-specific design. Together, these insights position MXenes as chemistry-programmable nanoplatforms with strong potential to bridge on-body, in-body, and outside-the-body biomedical technologies.
- Open Access
- 24 June 2026
- Published by Elsevier in Current Problems in Surgery
- Vol. 82
Effect of Polypropylene Mesh with MXene-Containing Hydrogel on Adhesions in a Rat Hernia Model
- 24 June 2026
- Published by Elsevier in Current Problems in Surgery
- Vol. 82
Open AccessEffect of Polypropylene Mesh with MXene-Containing Hydrogel on Adhesions in a Rat Hernia Model
- Open Access
- 27 July 2025
- Published by Wiley in Advanced NanoBiomed Research
- Vol. 5 (11)
Dual‐Action 3D Bioprinted Scaffolds with MXene Quantum Dots for Tumor Suppression and Breast Tissue Regeneration Postmastectomy
Breast cancer remains among the most prevalent malignancies affecting women globally. Current treatment approaches, including mastectomy, chemotherapy, and radiotherapy, often fail to prevent cancer recurrence and can result in substantial tissue damage, esthetic concerns, and diminished quality of life. Three‐dimensional (3D) bioprinting, stem cell‐based technologies, and MXene nanomaterials show promise in tissue repair and cancer treatment. However, there is a lack of strategies that can offer multiple effects, preventing both breast tissue regeneration and tumor recurrence. In this study, we developed 3D hydrogel scaffolds incorporating stem cells and MXene quantum dots (MQDs) for in vivo application in a mouse model of breast cancer. We compared cellular, acellular, cellular MQD, and acellular MQD scaffolds transplanted into mouse after tumor resection and mastectomy. Notably, the acellular MQD group showed no tumor recurrence by day 14. It demonstrated superior tissue regeneration, confirmed by histological and immunostaining analyses. As a result, we offer a nanotechnological 3D scaffold based on hydrogel with dual functionality in preventing tumor recurrence and facilitating tissue regeneration. This innovative approach has the potential to revolutionize breast cancer treatment by reducing dependence on chemotherapy and radiotherapy. Thus, it offers a promising alternative for improving patient treatment outcomes.
- 27 July 2025
- Published by Wiley in Advanced NanoBiomed Research
- Vol. 5 (11)
Open AccessDual‐Action 3D Bioprinted Scaffolds with MXene Quantum Dots for Tumor Suppression and Breast Tissue Regeneration Postmastectomy
Breast cancer remains among the most prevalent malignancies affecting women globally. Current treatment approaches, including mastectomy, chemotherapy, and radiotherapy, often fail to prevent cancer recurrence and can result in substantial tissue damage, esthetic concerns, and diminished quality of life. Three‐dimensional (3D) bioprinting, stem cell‐based technologies, and MXene nanomaterials show promise in tissue repair and cancer treatment. However, there is a lack of strategies that can offer multiple effects, preventing both breast tissue regeneration and tumor recurrence. In this study, we developed 3D hydrogel scaffolds incorporating stem cells and MXene quantum dots (MQDs) for in vivo application in a mouse model of breast cancer. We compared cellular, acellular, cellular MQD, and acellular MQD scaffolds transplanted into mouse after tumor resection and mastectomy. Notably, the acellular MQD group showed no tumor recurrence by day 14. It demonstrated superior tissue regeneration, confirmed by histological and immunostaining analyses. As a result, we offer a nanotechnological 3D scaffold based on hydrogel with dual functionality in preventing tumor recurrence and facilitating tissue regeneration. This innovative approach has the potential to revolutionize breast cancer treatment by reducing dependence on chemotherapy and radiotherapy. Thus, it offers a promising alternative for improving patient treatment outcomes.
- 6 March 2020
- Published by Springer Nature in 3 Biotech
- Vol. 10 (4) , 1-13
Where is human-based cellular pharmaceutical R&D taking us in cartilage regeneration?
Lately, cellular-based cartilage joint therapies have gradually gained more attention, which leads to next generation bioengineering approaches in the development of cell-based medicinal products for human use in cartilage repair. The greatest hurdles of chondrocyte-based cartilage bioengineering are: (i) preferring the cell source; (ii) differentiation and expansion processes; (iii) the time necessary for chondrocyte expansion pre-implantation; and (iv) fixing the chondrocyte count in accordance with the lesion surface area of the patient in question. The chondrocyte presents itself to be the focal starting material for research and development of bioengineered cartilage-based medicinal products which promise the regeneration and restoration of non-orthopedic cartilage joint defects. Even though chondrocytes seem to be the first choice, inevitable complications related to proliferation, dedifferentation and redifferentiation are probable. Detailed studies are a necessity to fully investigate detailed culturing conditions, the chondrogenic strains of well-defined phenotypes and evaluation of the methods to be used in biomaterial production. Despite a majority of the current methods which aid amelioration of joint functionality, they are insufficient in fully restoring the natural structure and composition of the joint cartilage. Hence current studies have trended towards gene therapy, mesenchymal stem cells and tissue engineering practices. There are many studies addressing the outcomes of chondrocytes in the clinical scene, and many vital biomaterials have been developed for structuring the bioengineered cartilage. This study aims to convey to the audience the practical significance of chondrocyte-based clinical applications.
- 6 March 2020
- Published by Springer Nature in 3 Biotech
- Vol. 10 (4) , 1-13
Where is human-based cellular pharmaceutical R&D taking us in cartilage regeneration?
Lately, cellular-based cartilage joint therapies have gradually gained more attention, which leads to next generation bioengineering approaches in the development of cell-based medicinal products for human use in cartilage repair. The greatest hurdles of chondrocyte-based cartilage bioengineering are: (i) preferring the cell source; (ii) differentiation and expansion processes; (iii) the time necessary for chondrocyte expansion pre-implantation; and (iv) fixing the chondrocyte count in accordance with the lesion surface area of the patient in question. The chondrocyte presents itself to be the focal starting material for research and development of bioengineered cartilage-based medicinal products which promise the regeneration and restoration of non-orthopedic cartilage joint defects. Even though chondrocytes seem to be the first choice, inevitable complications related to proliferation, dedifferentation and redifferentiation are probable. Detailed studies are a necessity to fully investigate detailed culturing conditions, the chondrogenic strains of well-defined phenotypes and evaluation of the methods to be used in biomaterial production. Despite a majority of the current methods which aid amelioration of joint functionality, they are insufficient in fully restoring the natural structure and composition of the joint cartilage. Hence current studies have trended towards gene therapy, mesenchymal stem cells and tissue engineering practices. There are many studies addressing the outcomes of chondrocytes in the clinical scene, and many vital biomaterials have been developed for structuring the bioengineered cartilage. This study aims to convey to the audience the practical significance of chondrocyte-based clinical applications.